We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54 | -0.83% | 64.79 | 64.71 | 64.82 | 65.53 | 64.33 | 65.51 | 7,822,721 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
Gilead Sciences Inc. (GILD) and Goldfinch Bio Inc. said Wednesday they would develop and commercialize therapeutics for diabetic kidney disease and some orphan kidney diseases.
Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch's Kidney Genome Atlas, a registry of patients with kidney diseases.
Goldfinch will receive $55 million in upfront payments, including a $5 million equity investment, and an additional $54 million to support the development of the KGA platform for diabetic kidney disease. Goldfinch also is eligible for up to $1.95 billion in potential payments for the first five collaboration programs based on research, development, regulatory and commercial milestones, and tiered royalties.
Gilead shares were down about 1% premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 08, 2019 08:13 ET (12:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
